KRAS


Also found in: Dictionary, Acronyms, Encyclopedia, Wikipedia.
Related to KRAS: Moravsky Kras

KRAS

A Kirsten ras oncogene homolog from the mammalian ras gene family on chromosome 12p12.1, which encodes a small GTPase in which a single amino acid substitution results in a transforming protein.

Molecular pathology
The KRAS transforming protein has been linked to various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas, colorectal carcinoma, acute myelogenous leukaemia, juvenile myelomonocytic leukaemia, gastric cancer, pilocytic astrocytoma, Noonan syndrome type 3, and cardiofaciocutaneous syndrome
References in periodicals archive ?
Inhibiting KRAS signaling has been tricky because it lacks good pockets or crevices for small molecules and drugs to bind to.
KRAS is a protooncogene that encodes proteins involved in cell growth, division, motility, differentiation, and apoptosis.
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.
Introduction of the therascreen KRAS test provides an FDA-approved diagnostic available for making treatment decisions for colorectal cancer patients.
Unlike women with BRCA mutations who develop ovarian cancer at a relatively young age, patients with the KRAS variant tended to become ill after the menopause.
KRAS hastalarinin %50'sinde aktif hareket acikliginda azalma, fizyolojik tremor amplitudunde artma ve etkilenen ekstremitede aktif motor gucte gerileme vardir.
The researchers also determined KRAS status in tumor samples from 48 of the patients, and correlated this status with overall response and progression-free survival.
Abstract title: Dynamics of KRAS G12/13 allele burden in circulating tumor DNA predicts survival in patients with unresectable pancreatic cancer undergoing palliative chemotherapy
For example, KRAS [8] (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) gene mutations, which are present in 40% of colorectal adenocarcinomas, are predictive markers of nonresponse to anti-epidermal growth factor receptor (anti-EGFR) [9] antibodies (4-6), and BRAF (protooncogene B-Raf, serine/threonine-protein kinase B-Raf) mutations have been shown to be associated with poor prognosis (7).
Key secondary endpoints included progression-free survival (PFS) in patients with wild-type KRAS mCRC, as well as OS and PFS in patients with wild-type RAS(absence of mutations in exons 2, 3 and 4 of KRAS and NRAS) mCRC.